

Vladimir Maisnar

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/8013193/publications.pdf>

Version: 2024-02-01

69
papers

2,012
citations

566801

15
h-index

243296

44
g-index

73
all docs

73
docs citations

73
times ranked

2494
citing authors

#	ARTICLE	IF	CITATIONS
1	Carfilzomib, Lenalidomide, and Dexamethasone for Relapsed Multiple Myeloma. <i>New England Journal of Medicine</i> , 2015, 372, 142-152.	13.9	1,144
2	Carfilzomib significantly improves the progression-free survival of high-risk patients in multiple myeloma. <i>Blood</i> , 2016, 128, 1174-1180.	0.6	110
3	A randomized phase III study of carfilzomib vs low-dose corticosteroids with optional cyclophosphamide in relapsed and refractory multiple myeloma (FOCUS). <i>Leukemia</i> , 2017, 31, 107-114.	3.3	98
4	Triplet vs doublet lenalidomide-containing regimens for the treatment of elderly patients with newly diagnosed multiple myeloma. <i>Blood</i> , 2016, 127, 1102-1108.	0.6	78
5	IgM myeloma: A multicenter retrospective study of 134 patients. <i>American Journal of Hematology</i> , 2017, 92, 746-751.	2.0	45
6	Patient-reported health-related quality of life from the phase III TOURMALINE-MM1 study of ixazomib+lenalidomide+dexamethasone versus placebo+lenalidomide+dexamethasone in relapsed/refractory multiple myeloma. <i>American Journal of Hematology</i> , 2018, 93, 985-993.	2.0	41
7	Complex karyotype and translocation t(4;14) define patients with high-risk newly diagnosed multiple myeloma: results of CMG2002 trial. <i>Leukemia and Lymphoma</i> , 2012, 53, 920-927.	0.6	36
8	Response and progression-free survival according to planned treatment duration in patients with relapsed multiple myeloma treated with carfilzomib, lenalidomide, and dexamethasone (KRd) versus lenalidomide and dexamethasone (Rd) in the phase III ASPIRE study. <i>Journal of Hematology and Oncology</i> , 2018, 11, 49.	6.9	33
9	Subcutaneous Bortezomib in Multiple Myeloma Patients Induces Similar Therapeutic Response Rates as Intravenous Application But It Does Not Reduce the Incidence of Peripheral Neuropathy. <i>PLoS ONE</i> , 2015, 10, e0123866.	1.1	32
10	Cutaneous involvement in multiple myeloma: a multi-institutional retrospective study of 53 patients. <i>Leukemia and Lymphoma</i> , 2016, 57, 2071-2076.	0.6	30
11	Limited efficacy of daratumumab in multiple myeloma with extramedullary disease. <i>Leukemia</i> , 2022, 36, 288-291.	3.3	23
12	Survival benefit of ixazomib, lenalidomide and dexamethasone (IRD) over lenalidomide and dexamethasone (Rd) in relapsed and refractory multiple myeloma patients in routine clinical practice. <i>BMC Cancer</i> , 2021, 21, 73.	1.1	20
13	High-dose chemotherapy followed by autologous stem cell transplantation changes prognosis of IgD multiple myeloma. <i>Bone Marrow Transplantation</i> , 2008, 41, 51-54.	1.3	19
14	Isatuximab plus pomalidomide and dexamethasone in patients with relapsed/refractory multiple myeloma according to prior lines of treatment and refractory status: ICARIA-MM subgroup analysis. <i>Leukemia Research</i> , 2021, 104, 106576.	0.4	19
15	Isotype class switching after transplantation in multiple myeloma. <i>Neoplasma</i> , 2007, 54, 225-8.	0.7	17
16	Real-world Outcomes of Multiple Myeloma: Retrospective Analysis of the Czech Registry of Monoclonal Gammopathies. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2018, 18, e219-e240.	0.2	16
17	Epidemiology of Multiple Myeloma in the Czech Republic. <i>Klinicka Onkologie</i> , 2017, 30, 2S35-2S42.	0.1	15
18	Identification of patients with smouldering multiple myeloma at ultra-high risk of progression using serum parameters: the Czech Myeloma Group model. <i>British Journal of Haematology</i> , 2020, 190, 189-197.	1.2	13

#	ARTICLE	IF	CITATIONS
19	Interference of IgM- λ paraprotein with biuret-type assay for total serum protein quantification. <i>Clinical Chemistry and Laboratory Medicine</i> , 2009, 47, 235-6.	1.4	12
20	Ixazomib-lenalidomide-dexamethasone in routine clinical practice: effectiveness in relapsed/refractory multiple myeloma. <i>Future Oncology</i> , 2021, 17, 2499-2512.	1.1	11
21	Registry of Monoclonal Gammopathies (RMG) in the Czech Republic. <i>Blood</i> , 2015, 126, 4514-4514.	0.6	11
22	Association Study of Selected Genetic Polymorphisms and Occurrence of Venous Thromboembolism in Patients With Multiple Myeloma Who Were Treated With Thalidomide. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2011, 11, 414-420.	0.2	10
23	Quality of life is maintained with ixazomib maintenance in post-transplant newly diagnosed multiple myeloma: The TOURMALINE-MM3 trial. <i>European Journal of Haematology</i> , 2020, 104, 443-458.	1.1	10
24	Single agent daratumumab in advanced multiple myeloma possesses significant efficacy even in an unselected "real-world" population. <i>Biomedical Papers of the Medical Faculty of the University Palacky&#x0301;, Olomouc, Czechoslovakia</i> , 2019, 163, 279-283.	0.2	10
25	Monotherapy with low-dose thalidomide for relapsed or refractory multiple myeloma: better response rate with earlier treatment. <i>European Journal of Haematology</i> , 2007, 79, 305-309.	1.1	9
26	Prediction of Progression of Smouldering into Therapy Requiring Multiple Myeloma By Easily Accessible Clinical Factors [in 527 Patients]. <i>Blood</i> , 2014, 124, 2071-2071.	0.6	9
27	International Staging System required standardization of biochemical laboratory testing in multiple myeloma. <i>Neoplasma</i> , 2006, 53, 492-4.	0.7	9
28	Immunoparesis in MGUS – Relationship of uninvolved immunoglobulin pair suppression and polyclonal immunoglobuline levels to MGUS risk categories. <i>Neoplasma</i> , 2015, 62, 827-832.	0.7	8
29	Multicentered patient-based evidence of the role of free light chain ratio normalization in multiple myeloma disease relapse. <i>European Journal of Haematology</i> , 2016, 96, 119-127.	1.1	8
30	Efficacy and Safety of Carfilzomib, Lenalidomide, and Dexamethasone Vs Lenalidomide and Dexamethasone in Patients with Relapsed Multiple Myeloma Based on Cytogenetic Risk Status: Subgroup Analysis from the Phase 3 Study Aspire (NCT01080391). <i>Blood</i> , 2015, 126, 731-731.	0.6	8
31	Identification of patients at high risk of secondary extramedullary multiple myeloma development. <i>British Journal of Haematology</i> , 2021, , .	1.2	8
32	Interlaboratory study of free monoclonal immunoglobulin light chain quantification. <i>Clinical Chemistry and Laboratory Medicine</i> , 2011, 49, 89-92.	1.4	7
33	A first Czech analysis of 1887 cases with monoclonal gammopathy of undetermined significance. <i>European Journal of Haematology</i> , 2017, 99, 80-90.	1.1	7
34	Methodology and results of real-world cost-effectiveness of carfilzomib in combination with lenalidomide and dexamethasone in relapsed multiple myeloma using registry data. <i>European Journal of Health Economics</i> , 2020, 21, 219-233.	1.4	7
35	Diagnosis and surgical therapy of plasma cell neoplasia of the spine. <i>Neoplasma</i> , 2009, 56, 84-87.	0.7	7
36	Solitary Extramedullary Plasmacytoma in the Oropharynx: Advantages of Intensity-Modulated Radiation Therapy. <i>Clinical Lymphoma and Myeloma</i> , 2007, 7, 434-437.	1.4	6

#	ARTICLE	IF	CITATIONS
37	The problems of proteinuria measurement in urine with presence of Bence Jones protein. <i>Clinical Biochemistry</i> , 2011, 44, 403-405.	0.8	6
38	Validation of multiple myeloma risk stratification indices in routine clinical practice: Analysis of data from the Czech Myeloma Group Registry of Monoclonal Gammopathies. <i>Cancer Medicine</i> , 2018, 7, 4132-4145.	1.3	6
39	Treatment of associated anemia in different hematological disorders with epoetin alpha. <i>Neoplasma</i> , 2004, 51, 379-84.	0.7	6
40	The significance of soluble CD138 in diagnosis of monoclonal gammopathies. <i>Neoplasma</i> , 2006, 53, 26-9.	0.7	6
41	Czech Registry of Monoclonal Gammopathies – Technical Solution, Data Collection and Visualisation. <i>Klinicka Onkologie</i> , 2017, 30, 2S43-2S50.	0.1	5
42	Capillary immunotyping electrophoresis and high resolution two-dimensional electrophoresis for the detection of λ /4-heavy chain disease. <i>Clinica Chimica Acta</i> , 2008, 389, 171-173.	0.5	4
43	Lenalidomide and dexamethasone in treatment of patients with relapsed and refractory multiple myeloma – analysis of data from the Czech Myeloma Group Registry of Monoclonal Gammopathies. <i>Neoplasma</i> , 2019, 66, 499-505.	0.7	4
44	Improvement of Anaemia in Patients with Primary Myelofibrosis by Low-Dose Thalidomide and Prednisone. <i>Acta Medica (Hradec Kralove)</i> , 2016, 59, 50-53.	0.2	4
45	10 years of experience with thalidomide in multiple myeloma patients: Report of the Czech Myeloma Group. <i>Leukemia Research</i> , 2013, 37, 1063-1069.	0.4	3
46	Multiple Myeloma R-ISS Prognostic Stratification System in Real Life Population. <i>Blood</i> , 2016, 128, 3333-3333.	0.6	3
47	Simplified novel prognostic score for real-life older adults with multiple myeloma – registry-based analysis. <i>Annals of Hematology</i> , 2019, 98, 951-962.	0.8	2
48	Overall Survival Benefit of Ixazomib, Lenalidomide and Dexamethasone (IRD) over Lenalidomide and Dexamethasone (RD) in RRMM Patients Treated in Routine Clinical Practice: Results from the Czech Registry of Monoclonal Gammopathies (RMG). <i>Blood</i> , 2019, 134, 3139-3139.	0.6	2
49	Bortezomib retreatment is effective in relapsed multiple myeloma patients – real-life clinical practice data. <i>Neoplasma</i> , 2020, 67, 178-184.	0.7	2
50	Monoclonal gammopathies in a series of 1743 plasma donors. <i>Acta Medica (Hradec Kralove)</i> , 2006, 49, 119-21.	0.2	2
51	The Czech National External Quality Assessment of monoclonal immunoglobulin in the period of 1996 - 2005. <i>Neoplasma</i> , 2008, 55, 61-4.	0.7	2
52	Severe anemia caused by combination of autoimmune hemolysis, pure red cell aplasia and massive bone marrow infiltration in an elderly patient with chronic lymphocytic leukemia: Successful treatment with rituximab. <i>Leukemia Research</i> , 2010, 34, e140-e141.	0.4	1
53	Successful radiotherapy treatment of lacrimal gland infiltration in patient with Sjögren's syndrome. <i>Bratislava Medical Journal</i> , 2012, 113, 249-250.	0.4	1
54	Bortezomib-based therapy for newly diagnosed multiple myeloma patients ineligible for autologous stem cell transplantation: Czech Registry Data. <i>European Journal of Haematology</i> , 2021, 107, 466-474.	1.1	1

#	ARTICLE	IF	CITATIONS
55	Urine immunofixation negativity is not necessary for complete response in intact immunoglobulin multiple myeloma: Retrospective real-world confirmation. International Journal of Laboratory Hematology, 2021, 43, e244-e247.	0.7	1
56	Evaluation of Current Clinical Models for Risk of Progression from Monoclonal Gammopathy of Undetermined Significance to Multiple Myeloma or Related Malignancies in 2028 Persons Followed in the Czech Republic. Blood, 2014, 124, 3376-3376.	0.6	1
57	Early Diagnosis of Multiple Myeloma - Project CRAB of Czech Myeloma Group(CMG). Blood, 2014, 124, 5682-5682.	0.6	1
58	Comparative Effectiveness of Daratumumab Monotherapy Versus a Real-World Historical Control from the Czech Republic in Heavily Pretreated and Highly Refractory Multiple Myeloma Patients. Blood, 2016, 128, 3332-3332.	0.6	1
59	Simple Prognostic Score for Evaluation of Elderly Multiple Myeloma Patients. Blood, 2016, 128, 5679-5679.	0.6	1
60	Follow-up Analysis of Ixazomib, Lenalidomide and Dexamethasone Versus Lenalidomide and Dexamethasone in Routine Clinical Practice. Blood, 2021, 138, 2716-2716.	0.6	1
61	Early Diagnosis of Multiple Myeloma - Project CRAB of Czech Myeloma Group(CMG). Clinical Lymphoma, Myeloma and Leukemia, 2015, 15, e93.	0.2	0
62	The Frequency of Venous Thromboembolism in Women with F V Leiden in Heterozygous Form from the East Bohemia Region in Association with Pregnancy and Puerperium.. Blood, 2004, 104, 4006-4006.	0.6	0
63	High-Dose Therapy and Autologous Stem Cell Transplantation for Multiple Myeloma: Analysis from Registry of Monoclonal Gammopathy of Czech Myeloma Group. Blood, 2012, 120, 4528-4528.	0.6	0
64	Subcutaneous and Intravenous Bortezomib in Multiple Myeloma Patients Has Similar Response Rates and Toxicity Profile with No Difference in the Incidence of Peripheral Neuropathy: Report of the Czech Myeloma Group. Blood, 2014, 124, 2117-2117.	0.6	0
65	Stem Cell Mobilization after Various Induction Regimens in Patients with Multiple Myeloma. Blood, 2015, 126, 5433-5433.	0.6	0
66	IgM Myeloma: A Multicenter Retrospective Study of 159 Patients. Blood, 2016, 128, 3276-3276.	0.6	0
67	Asymptomatic and Treatment-requiring Multiple Myeloma " Data from the Czech Registry of Monoclonal Gammopathies. Klinicka Onkologie, 2017, 30, 2S51-2S59.	0.1	0
68	Whole Exome Sequencing of Aberrant Plasma Cells in a Patient with Multiple Myeloma Minimal Residual Disease. Klinicka Onkologie, 2017, 30, 2S75-2S80.	0.1	0
69	Survival Analysis of Newly Diagnosed Transplant-Eligible Multiple Myeloma Patients in Czech Republic. Blood, 2021, 138, 4894-4894.	0.6	0